ELI LILLY AND COMPANY
Insulin lispro (marketed by Lilly as "Humalog") is a fast acting insulin analogue; it was the first insulin analogue.
It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections. It has been shown by Shimoda et al. that, when comparing three insulin delivery methods, i.v. (intravenous) regular insulin, s.c. (subcutaneous) insulin Lispro, and s.c. regular insulin, that s.c. insulin Lispro performs almost as well as i.v. regular insulin in handling meal disturbances. S.c. regular insulin performed worse than s.c. insulin lispro, resulting in postprandial glucose peaks, in addition to postprandial hypoglycemia.
1. ^ [http://www.aafp.org/afp/980115ap/noble.html Insulin Lispro: A Fast-Acting Insulin Analog]. Retrieved on 2007-06-08.